2024 The Royal College of Physicians of Thailand (RCPT) clinical practice guidelines on management of dyslipidemia for atherosclerotic cardiovascular disease prevention
12
Issued Date
2024-12-01
Resource Type
ISSN
19057415
eISSN
1875855X
Scopus ID
2-s2.0-85213036710
Journal Title
Asian Biomedicine
Volume
18
Issue
6
Start Page
246
End Page
267
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Biomedicine Vol.18 No.6 (2024) , 246-267
Suggested Citation
Lolekha P., Khovidhunkit W., Deerochanawong C., Thongtang N., Boonyasirinant T., Rattarasarn C., Chutinet A., Ophascharoensuk V., Somlaw N., Sitthisook S., Suntorntham S., Nitiyanant W., Krittayaphong R. 2024 The Royal College of Physicians of Thailand (RCPT) clinical practice guidelines on management of dyslipidemia for atherosclerotic cardiovascular disease prevention. Asian Biomedicine Vol.18 No.6 (2024) , 246-267. 267. doi:10.2478/abm-2024-0033 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/102576
Title
2024 The Royal College of Physicians of Thailand (RCPT) clinical practice guidelines on management of dyslipidemia for atherosclerotic cardiovascular disease prevention
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: The Royal College of Physicians of Thailand (RCPT) published a Clinical Practice Guideline on Pharmacologic Therapy of Dyslipidemia for Atherosclerotic Cardiovascular Disease (ASCVD) Prevention in 2016. The availability of newer classes of medications for dyslipidemia, supported by extensive clinical research findings, indicates a significant need for the updating of the existing clinical practice guideline. Objectives: To serve as guidelines on the management of dyslipidemia for Thai adults. Methods: The RCPT Dyslipidemia Guidelines Committee was established with representatives from selected professional societies to revise the 2016 Guideline by critically reviewing the latest evidence. Meetings were conducted from August to December 2023, culminating in a public hearing that engaged various stakeholders in January 2024. The final Thai version received approval in April 2024, while the English translation was completed in October 2024. Results: Lifestyle modifications and statins remain the cornerstone of therapy for dyslipidemia in adults across various clinical settings. Emerging evidence regarding newer classes of lipid-lowering medications indicates that these treatments are effective in lowering LDL-cholesterol levels and reducing atherosclerotic cardiovascular events. This suggests that they may serve as an add-on therapy for individuals who cannot achieve target levels or who are at high risk for future cardiovascular events. The Thai CV Risk Score is recommended due to its specificity for the Thai population. Conclusions: The 2024 updated clinical practice guidelines establish a framework, provide recommendations, and serve as a comprehensive resource for the contemporary management of dyslipidemia in adults, with the goal of preventing ASCVD in Thailand.